
With respect to antiplatelet therapy, there also are no
randomized clinical trials assessing the beneÔ¨Åt of aspirin
vs dual therapy with aspirin and clopidogrel for patients
undergoing CAS. Current recommendations are therefore largely based on experience with coronary artery
stents. Dual antiplatelet therapy including aspirin
(325 mg) and clopidogrel (75 mg) should be initiated
before CAS, and continued for 4 weeks after the